Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Itraconazole Repurposing to Reduce Residual Cancer Risk in Patients With High-risk Barrett's Esophagus After Ablation

NCT05609253 is registered in ClinicalTrials.gov with University of Kansas Medical Center as lead sponsor.

NCT NCT05609253
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05609253 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Itraconazole Repurposing to Reduce Residual Cancer Risk in Patients With High-risk Barrett's Esophagus After Ablation
Lead sponsor
University of Kansas Medical Center
Phase
Phase 1
Overall status
Active, not recruiting
Start date
September 14, 2022
Completion date
December 30, 2026
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

barrett oesophagitis with dysplasia